NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Looking at that slide deck again, it really is amazing to me that over 10% of patients with incomplete surgeries that left significant residual tumor, when treated initially with DCVax-l, lived over five years.

The DCVax-L trial was the only one with "intent for near complete resection". Others allowed partials and even biopises.

Wonder if those with more than 1 cm^2 left (the cut line for MRD) in the DCVax-L trial that do have SRD are likely much more like the MRD population?

This is in addition to the fact that the 3 main variables, age/meth/extent all favored DCVax-L and the results presented did not adjust for that. Oh, they do have adjusted numbers, but did not want to show them.